{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:06:14Z","timestamp":1785546374293,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ConTIPI Medical Ltd","award":["none"],"award-info":[{"award-number":["none"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We evaluated a novel disposable, collapsible, ring-shaped vaginal device that is self-inserted within an applicator and removed with a string. The device was developed to overcome the drawbacks of existing ring pessaries for non-surgical pelvic organ prolapse management (POP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The primary objective efficacy endpoint of this prospective, interventional, multicenter, self-controlled, and home-use study was the proportion of subjects with improved staging on the Pelvic Organ Prolapse Quantification (POP-Q) scale. Subjective efficacy was assessed using the POP symptoms alleviation score. Safety was evaluated by recording the rate and incidence of adverse events (AEs) in a daily diary, and quality of life (QoL) was evaluated using the modified Pelvic Floor Impact (PFIQ-7) and Pelvic Floor Disability Index (PFDI-20) questionnaires.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 94 usage cycles were observed in a group of 52 participants (mean age 60.2\u2009\u00b1\u200910.5\u2009years, 81.1% postmenopausal) who used the device for 3558\u2009days. Of these, 24 participants completed one usage cycle, 14 completed two usage cycles, and 14 completed three usage cycles with 28\u201345\u2009days of ProVate use in each usage cycle. All patients experienced greater than two POP-Q stage reductions. The descent was completely reduced to POP-Q stage 0 in 97.8% of participants. The POP symptom alleviation questionnaire showed significant subjective efficacy (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). The modified PFDI-20 and PFIQ-7 scores also improved substantially (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001 for both). There were 91 nonserious device-related AEs: 98.9% were mild and 87.9% anticipated, with no vaginal infection, and one case of urinary tract infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The novel device substantially reduces prolapse and provides significant subjective POP symptom relief and QoL improvement, with minimal AEs. The device may enable women to self-manage their prolapse with a small, disposable device that minimizes self-touching and frequent dependency on the clinic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinical.trials.gov\">Clinical.Trials.gov<\/jats:ext-link>, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02239133?term=NCT02239133&amp;draw=2&amp;rank=1\">NCT02239133<\/jats:ext-link>, posted September 12, 2014 (retrospectively registered).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-022-02057-6","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T12:03:05Z","timestamp":1668772985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Novel, disposable, self-inserted, vaginal device for the non-surgical management of pelvic organ prolapse: efficacy, safety, and quality of life"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7187-6048","authenticated-orcid":false,"given":"Elan","family":"Ziv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsvia","family":"Erlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"2057_CR1","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1001\/jama.300.11.1311","volume":"300","author":"I Nygaard","year":"2008","unstructured":"Nygaard I, Barber MD, Burgio KL, Kenton K, Meikle S, Schaffer J, et al. Prevalence of symptomatic pelvic floor disorders in US women. JAMA. 2008;300:1311\u20136. https:\/\/doi.org\/10.1001\/jama.300.11.1311.","journal-title":"JAMA."},{"key":"2057_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00192-005-1326-1","volume":"16","author":"G Tegerstedt","year":"2005","unstructured":"Tegerstedt G, Maehle-Schmidt M, Nyr\u00e9n O, Hammarstr\u00f6m M. Prevalence of symptomatic pelvic organ prolapse in a Swedish population. Int Urogynecol J Pelvic Floor Dysfunct. 2005;16:497\u2013503. https:\/\/doi.org\/10.1007\/s00192-005-1326-1.","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"2057_CR3","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1097\/01.AOG.0000263469.68106","volume":"109","author":"MD Rortveit Guri","year":"2007","unstructured":"Rortveit Guri MD, Brown JS, Thom DH, Van Den Eeden SK, Creasman JM, Subak LL. Symptomatic pelvic organ prolapse: prevalence and risk factors in a population-based, racially diverse cohort. Obstet Gynecol. 2007;109:1396\u2013403. https:\/\/doi.org\/10.1097\/01.AOG.0000263469.68106.","journal-title":"Obstet Gynecol"},{"key":"2057_CR4","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s00192-013-2169-9","volume":"24","author":"MD Barber","year":"2013","unstructured":"Barber MD, Maher C. Epidemiology and outcome assessment of pelvic organ prolapse. Int Urogynecol J. 2013;24:1783\u201390. https:\/\/doi.org\/10.1007\/s00192-013-2169-9.","journal-title":"Int Urogynecol J"},{"key":"2057_CR5","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1097\/AOG.0b013e3181c2ce96","volume":"114","author":"JM Wu","year":"2009","unstructured":"Wu JM, Hundley AF, Fulton RG, Myers ER. Forecasting the prevalence of pelvic floor disorders in U.S. Women: 2010-2050. Obstet Gynecol. 2009;114:1278\u201383. https:\/\/doi.org\/10.1097\/AOG.0b013e3181c2ce96.","journal-title":"Obstet Gynecol"},{"key":"2057_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/nau.22298","volume":"32","author":"AS Gilchrist","year":"2013","unstructured":"Gilchrist AS, Campbell W, Steele H, Brazell H, Foote J, Swift S. Outcomes of observation as therapy for pelvic organ prolapse: A study in the natural history of pelvic organ prolapse. Neurourol Urodyn. 2013;32:383\u20136. https:\/\/doi.org\/10.1002\/nau.22298.","journal-title":"Neurourol Urodyn"},{"key":"2057_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ogc.2009.08.010","volume":"36","author":"SD Atnip","year":"2009","unstructured":"Atnip SD. Pessary use and management for pelvic organ prolapse. Obstet Gynecol Clin N Am. 2009;36:541\u201363. https:\/\/doi.org\/10.1016\/j.ogc.2009.08.010.","journal-title":"Obstet Gynecol Clin N Am"},{"key":"2057_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/ajo.13152","volume":"60","author":"F Turel Fatakia","year":"2020","unstructured":"Turel Fatakia F, Pixton S, Caudwell Hall J, Dietz HP. Predictors of successful ring pessary use in women with pelvic organ prolapse. Aust N Z J Obstet Gynaecol. 2020;60:579\u201384. https:\/\/doi.org\/10.1111\/ajo.13152.","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"2057_CR9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.ajog.2004.10.602","volume":"192","author":"S Swift","year":"2005","unstructured":"Swift S, Woodman P, O\u2019boyle A, Kahn M, Valley M, Bland D, et al. Pelvic Organ Support Study (POSST): the distribution, clinical definition, and epidemiologic condition of pelvic organ support defects. Am J Obstet Gynecol. 2005;192:795\u2013806. https:\/\/doi.org\/10.1016\/j.ajog.2004.10.602.","journal-title":"Am J Obstet Gynecol"},{"key":"2057_CR10","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/1471-0528.16950","volume":"129","author":"LR van der Vaart","year":"2022","unstructured":"van der Vaart LR, Vollebregt A, Milani AL, Lagro-Janssen AL, Duijnhoven RG, Roovers JP, et al. Pessary or surgery for a symptomatic pelvic organ prolapse: the PEOPLE study, a multicentre prospective cohort study. BJOG. 2022;129:820\u20139. https:\/\/doi.org\/10.1111\/1471-0528.16950.","journal-title":"BJOG."},{"key":"2057_CR11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S1701-2163(15)30888-4","volume":"35","author":"M Robert","year":"2013","unstructured":"Robert M, Schulz JA, Harvey MA, Lovatsis D, Walter JE, Chou Q, Easton WA, et al. Technical update on pessary use. J Obstet Gynaecol Can. 2013;35:664\u201374. https:\/\/doi.org\/10.1016\/S1701-2163(15)30888-4.","journal-title":"J Obstet Gynaecol Can"},{"key":"2057_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/s0002-9378(96)70243-0","volume":"175","author":"RC Bump","year":"1996","unstructured":"Bump RC, Mattiasson A, B\u00f8 K, Brubaker LP, DeLancey JO, Klarskov P, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol. 1996;175:10\u20137. https:\/\/doi.org\/10.1016\/s0002-9378(96)70243-0.","journal-title":"Am J Obstet Gynecol"},{"key":"2057_CR13","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.ajog.2006.01.076","volume":"194","author":"MD Barber","year":"2006","unstructured":"Barber MD, Walters MD, Cundiff GW, PESSRI Trial Group. Responsiveness of the Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ) in women undergoing vaginal surgery and pessary treatment for pelvic organ prolapse. Am J Obstet Gynecol. 2006;194:1492\u20138. https:\/\/doi.org\/10.1016\/j.ajog.2006.01.076.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"2057_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jogc.2020.11.013","volume":"43","author":"MA Harvey","year":"2021","unstructured":"Harvey MA, Lemieux MC, Robert M, Schulz JA. Guideline No. 411: Vaginal Pessary Use. J Obstet Gynaecol Can. 2021;43(2):255\u2013266.e1. Epub 2020 Nov 26. PMID: 33248302. https:\/\/doi.org\/10.1016\/j.jogc.2020.11.013.","journal-title":"J Obstet Gynaecol Can"},{"key":"2057_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00192-021-04775-1","volume":"33","author":"SC de Albuquerque Coelho","year":"2022","unstructured":"de Albuquerque Coelho SC, Pereira GMV, Brito LGO, Juliato CRT. Cross sectional study on assessment of ring pessary cleaning and removal every six months: adverse events and complications. Int Urogynecol J. 2022;33:397\u2013403. https:\/\/doi.org\/10.1007\/s00192-021-04775-1.","journal-title":"Int Urogynecol J"},{"key":"2057_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00192-005-1362-x","volume":"17","author":"LAM Hanson","year":"2006","unstructured":"Hanson LAM, Schulz JA, Flood CG, Cooley B, Tam F. Vaginal pessaries in managing women with pelvic organ prolapse and urinary incontinence: patient characteristics and factors contributing to success. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17:155\u20139. https:\/\/doi.org\/10.1007\/s00192-005-1362-x.","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"2057_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00192-004-1226-9","volume":"16","author":"SW Bai","year":"2005","unstructured":"Bai SW, Yoon BS, Kwon JY, Shin JS, Kim SK, Park KH. Survey of the characteristics and satisfaction degree of the patients using a pessary. Int Urogynecol J Pelvic Floor Dysfunct. 2005;16:182\u20136; discussion 186. https:\/\/doi.org\/10.1007\/s00192-004-1226-9.","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"2057_CR18","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1111\/j.1471-0528.2009.02380.x","volume":"116","author":"S Sarma","year":"2009","unstructured":"Sarma S, Ying T, Moore KH. Long-term vaginal ring pessary use: discontinuation rates and adverse events. BJOG. 2009;116:1715\u201321. https:\/\/doi.org\/10.1111\/j.1471-0528.2009.02380.x.","journal-title":"BJOG."},{"key":"2057_CR19","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s00192-016-3000-1","volume":"27","author":"SG Dessie","year":"2016","unstructured":"Dessie SG, Armstrong K, Modest AM, Hacker MR, Hota LS. Effect of vaginal estrogen on pessary use. Int Urogynecol J. 2016;27:1423\u20139. https:\/\/doi.org\/10.1007\/s00192-016-3000-1.","journal-title":"Int Urogynecol J"},{"key":"2057_CR20","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00192-016-2970-3","volume":"27","author":"S Ramsay","year":"2016","unstructured":"Ramsay S, Tu le le M, Tannenbaum C. Natural history of pessary use in women aged 65-74 versus 75 years and older with pelvic organ prolapse: a 12-year study. Int Urogynecol J. 2016;27:1201\u20137. https:\/\/doi.org\/10.1007\/s00192-016-2970-3.","journal-title":"Int Urogynecol J"},{"key":"2057_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00192-006-0089-7","volume":"18","author":"RJ Fernando","year":"2007","unstructured":"Fernando RJ, Sultan AH, Thakar R, Jeyanthan K. Management of the neglected vaginal ring pessary. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18:117\u20139. https:\/\/doi.org\/10.1007\/s00192-006-0089-7.","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"2057_CR22","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00192-021-04706-0","volume":"32","author":"A Miceli","year":"2021","unstructured":"Miceli A, Fern\u00e1ndez-S\u00e1nchez M, Due\u00f1as-D\u00edez JL. How often should ring pessaries be removed or changed in women with advanced POP? A prospective observational study. Int Urogynecol J. 2021;32:1471\u20138. https:\/\/doi.org\/10.1007\/s00192-021-04706-0.","journal-title":"Int Urogynecol J"},{"key":"2057_CR23","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00192-015-2686-9","volume":"26","author":"F Lone","year":"2015","unstructured":"Lone F, Thakar R, Sultan AH. One-year prospective comparison of vaginal pessaries and surgery for pelvic organ prolapse using the validated ICIQ-VS and ICIQ-UI (SF) questionnaires. Int Urogynecol J. 2015;26:1305\u201312. https:\/\/doi.org\/10.1007\/s00192-015-2686-9.","journal-title":"Int Urogynecol J"},{"key":"2057_CR24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00192-021-04717-x","volume":"33","author":"FG Gould","year":"2022","unstructured":"Gould FG, Carey MP, Plummer EL, Murray GL, Danielewski JA, Tabrizi SN. Garland SM Bacterial biofilm formation on vaginal ring pessaries used for pelvic organ prolapse. Int Urogynecol J. 2022;33:287\u201395. https:\/\/doi.org\/10.1007\/s00192-021-04717-x.","journal-title":"Int Urogynecol J"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-02057-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-022-02057-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-02057-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T12:05:21Z","timestamp":1668773121000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-022-02057-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2057"],"URL":"https:\/\/doi.org\/10.1186\/s12905-022-02057-6","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"assertion":[{"value":"12 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in line with the principles of the Declaration of Helsinki. Approval was granted by the institution\u2019s ethics committee (Assuta-Maccabi Helsinki committee, app #2014038).Written and informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EZ has a conflict of interest as he is an employee and shareholder at ConTIPI Medical who developed the studied device. EZ took part in the design of the study, data collection, interpretation of results and in manuscript writing.TS has a conflict of interest as she is a consultant and optionee at ConTIPI Medical who developed the studied device. TS took part in the design of the study, interpretation of results and in manuscript writing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"459"}}